Literature DB >> 24946181

AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.

Tz-Chuen Ju1, Hui-Mei Chen1, Yu-Chen Chen2, Ching-Pang Chang3, Chen Chang1, Yijuang Chern4.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurological disorder that is induced by a CAG trinucleotide expansion in exon 1 of the Huntingtin (HTT) gene. We previously reported that the abnormal activation of an important energy sensor, AMP-activated protein kinase α1 (AMPK-α1), occurs in the brains of mice and patients with HD, which suggests that this abnormal activation may contribute to neuronal degeneration in HD. In the present study, we demonstrated that the elevated oxidative stress that was evoked by a polyQ-expanded mutant HTT (mHTT) caused the abnormal activation of AMPK-α1 and, subsequently, resulted in neurotoxicity in a striatal progenitor cell line (STHdh(Q109)) and in the striatum of a transgenic mouse model of HD (R6/2). The systematic administration of an antioxidant (N-acetyl-cysteine, NAC) to R6/2 mice suppressed the activation of AMPK-α1, reduced neuronal toxicity, which was assessed by the activation of caspases, increased neuronal density, ameliorated ventricle enlargement, and improved motor dysfunction. This beneficial effect of NAC in vivo appears to be direct because NAC also reduced the activation of AMPK-α1 and the death of STHdh(Q109) cells upon elevated oxidative stress. Moreover, the activation of AMPK enhanced the level of oxidative stress in STHdh(Q109) cells, in primary neurons of R6/2 mice, and in the striatum of two different HD mouse models (R6/2 and Hdh(150Q/+)), whereas the inhibition of AMPK reduced the level of oxidative stress. Collectively, our findings suggest that positive feedback regulation between the elevated oxidative stress and the activation of AMPK-α1 contributes to the progression of HD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMP-activated protein kinase (AMPK); Huntington's disease (HD); N-acetyl-l-cysteine (NAC); Reactive oxygen species (ROS)

Mesh:

Substances:

Year:  2014        PMID: 24946181     DOI: 10.1016/j.bbadis.2014.06.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  AMP-activated protein kinase activation in mediating phenylalanine-induced neurotoxicity in experimental models of phenylketonuria.

Authors:  Lihua Lu; Xiaoming Ben; Lingling Xiao; Min Peng; Yongjun Zhang
Journal:  J Inherit Metab Dis       Date:  2017-12-11       Impact factor: 4.982

2.  Ginsenoside compound K reduces the progression of Huntington's disease via the inhibition of oxidative stress and overactivation of the ATM/AMPK pathway.

Authors:  Kuo-Feng Hua; A-Ching Chao; Ting-Yu Lin; Wan-Tze Chen; Yu-Chieh Lee; Wan-Han Hsu; Sheau-Long Lee; Hsin-Min Wang; Ding-I Yang; Tz-Chuen Ju
Journal:  J Ginseng Res       Date:  2021-11-11       Impact factor: 5.735

Review 3.  A comprehensive overview of PPM1A: From structure to disease.

Authors:  Mao Li; Xingfeng Xu; Yan Su; Xiaoyun Shao; Yali Zhou; Jianguo Yan
Journal:  Exp Biol Med (Maywood)       Date:  2021-12-03

Review 4.  Metabolic control of the proteotoxic stress response: implications in diabetes mellitus and neurodegenerative disorders.

Authors:  Kuo-Hui Su; Chengkai Dai
Journal:  Cell Mol Life Sci       Date:  2016-06-11       Impact factor: 9.261

5.  Auditory Pathology in a Transgenic mtTFB1 Mouse Model of Mitochondrial Deafness.

Authors:  Sharen E McKay; Wayne Yan; Jessica Nouws; Maximilian J Thormann; Nuno Raimundo; Abdul Khan; Joseph Santos-Sacchi; Lei Song; Gerald S Shadel
Journal:  Am J Pathol       Date:  2015-11-06       Impact factor: 4.307

6.  Remote Ischemic Post-Conditioning Therapy is Protective in Mouse Model of Traumatic Optic Neuropathy.

Authors:  Muhammad Nadeem; Adam Kindelin; Laura Mahady; Kanchan Bhatia; Md Nasrul Hoda; Andrew F Ducruet; Saif Ahmad
Journal:  Neuromolecular Med       Date:  2020-11-13       Impact factor: 3.843

7.  AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease.

Authors:  Rafael P Vázquez-Manrique; Francesca Farina; Karine Cambon; María Dolores Sequedo; Alex J Parker; José María Millán; Andreas Weiss; Nicole Déglon; Christian Neri
Journal:  Hum Mol Genet       Date:  2015-12-17       Impact factor: 6.150

8.  Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.

Authors:  Hong Cai; Edwina Scott; Abeer Kholghi; Catherine Andreadi; Alessandro Rufini; Ankur Karmokar; Robert G Britton; Emma Horner-Glister; Peter Greaves; Dhafer Jawad; Mark James; Lynne Howells; Ted Ognibene; Michael Malfatti; Christopher Goldring; Neil Kitteringham; Joanne Walsh; Maria Viskaduraki; Kevin West; Andrew Miller; David Hemingway; William P Steward; Andreas J Gescher; Karen Brown
Journal:  Sci Transl Med       Date:  2015-07-29       Impact factor: 17.956

Review 9.  Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling.

Authors:  Pooja Jadiya; Joanne F Garbincius; John W Elrod
Journal:  Acta Neuropathol Commun       Date:  2021-07-07       Impact factor: 7.801

10.  Chronic 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside Treatment Induces Phenotypic Changes in Skeletal Muscle, but Does Not Improve Disease Outcomes in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Marie-France Paré; Bernard J Jasmin
Journal:  Front Neurol       Date:  2017-09-27       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.